Tejvir Singh

Quality initiative in first-line chronic lymphocytic leukemia /small lymphocytic lymphoma assessing the use of 2nd generation BTKi therapy and impact on cardiac medical conditions patients experience on treatment

Jing‐Zhou Hou, Tejvir Singh, Patrick M. Travis, Olalekan Ajayi et autres

Abstract Background: Given the introduction of 2nd generation safer and more tolerable BTKis to treat first- line Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) patients, Integra Connect evaluated the use of these therapies among patients at practices who participated in its quality …

us (code pays fourni par la source)

Initial performance of pirtobrutinib: Real-world outcomes among CLL patients after prior covalent-BTKi and BCL2i use

Rushir J. Choksi, Aliakbar Dadla, Thomas Weart, Brian Patrick Mulherin et autres

Abstract Background: Non-covalent Bruton's tyrosine kinase inhibitors (BTKi) are third-generation BTKis that utilize non-covalent bonding to improve efficacy and safety by reducing unintended binding and off-target effects. A medication from this drug class, pirtobrutinib was approved by the FDA for chronic lymphocytic …

us (code pays fourni par la source)

Evaluation of real-world outcomes among CLL patients based on sequencing of BTKi and BCL2i therapies

Taral Patel, Rushir J. Choksi, Tejvir Singh, Aliakbar Dadla et autres

Abstract Background: Current first-line (1L) therapies for chronic lymphocytic leukemia (CLL) consist of Bruton tyrosine kinase inhibitors (BTKi) or B-cell lymphoma 2 inhibitors (BCL2i). However, many patients (pts) will require multiple therapies over the course of their treatment and often switch from …

us (code pays fourni par la source)

Response to: “Adverse effect of muscle damage due to osimertinib”

Pawel Parafianowicz, Rohee Krishan, Bryce David Beutler, Raheel X. Islam et autres

us (code pays fourni par la source)

Myositis – A common but underreported adverse effect of osimertinib: Case series and review of the literature

Pawel Parafianowicz, Rohee Krishan, Bryce David Beutler, Raheel X. Islam et autres

BACKGROUND: Lung cancer is the second most common cancer in both men and women and the leading cause of cancer death worldwide. The development of novel tyrosine kinase inhibitors (TKIs) represented a paradigm shift in the management of lung cancer and has …

us (code pays fourni par la source)

Metastatic Sclerosing Mucoepidermoid Carcinoma With Eosinophilia

Bryce David Beutler, Mark Bilinyi Ulanja, Mohit Rishi, Christie Elliott et autres

us (code pays fourni par la source)

EVALUATION OF CREACTIVE PROTEIN AND PROCALCITONIN IN SEPSIS

Muni Venkateswarlu, Tejvir Singh, K Saileela, P.LVasantha

Early diagnosis and appropriate therapy of sepsis is a daily challenge in the emergency room and in intensive care unit. In addition non infectious clinical syndromes can exhibit sepsis like symptoms, thereby making a diagnosis of sepsis more difficult . Today various …

in (code pays fourni par la source)

Strategies for Overcoming Imatinib Mesylate Resistance in Chronic Myelogenous Leukemia

Tejvir Singh, Connie Casson

Imatinib mesylate was approved for the treatment of chronic myelogenous leukemia more than 5 years ago. This drug enabled us to put a very high percentage of patients into hematologic, cytogenetic, and molecular remission. Some patients were resistant to Imatinib from the …

us (code pays fourni par la source)

Refining prognosis in non-small-cell lung cancer.

Tejvir Singh, Jasmine Dhindsa